Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 8/20 | 0.46 |
| ▸ | MET | P08581 | 3/20 | 0.46 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.42 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 6/20 | 0.41 |
| ▸ | CCNK | O75909 | 1/20 | 0.41 |
| ▸ | CCND3 | P30281 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.41 |
| ▸ | INSR | P06213 | 2/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2126616 | 0.89 | GLO1 (0.45) | ALKMETGLO1CCNA2CDK2 | |
| SCHEMBL2125821 | 0.87 | ALK (0.56) | ALKMETGLO1EGFRLRRK2 | |
| SCHEMBL2128811 | 0.86 | GLO1 (0.44) | ALKMETGLO1CCNA2CDK2 | |
| SCHEMBL2143511 | 0.83 | GLO1 (0.46) | ALKMETGLO1CCNA2CDK2 | |
| SCHEMBL2122602 | 0.83 | ALK (0.42) | ALKMETGLO1EGFRLRRK2 | |
| SCHEMBL2126996 | 0.79 | ALK (0.53) | ALKMETGLO1EGFRLRRK2 | |
| SCHEMBL1460877 | 0.78 | ALK (0.45) | ALKMETGLO1CCNA2CDK2 | |
| SCHEMBL2124144 | 0.78 | JAK2 (0.58) | ALKMETGLO1CDK2CDK9 | |
| SCHEMBL604128 | 0.76 | PTK2 (0.49) | ALKMETGLO1EGFRLRRK2 | |
| SCHEMBL600999 | 0.76 | ALK (0.47) | ALKMETGLO1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172384-A1 | HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2012-07-05 | — | — | US | claimed |
| US-20120172384-A1 | HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| EP-2443106-A1 | HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS | Cellzome Limited (GB) | 2012-04-25 | — | — | EP | disclosed |
| WO-2010146133-A1 | HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172384-A1 | HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS | ZAP70, JAK3, JAK2 | ALK 233/4885MET 2363/4885GLO1 3371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.